Literature DB >> 16728460

Development of comprehensive disease assessment in systemic vasculitis.

Oliver Flossmann1, Paul Bacon, Kirsten de Groot, David Jayne, Niels Rasmussen, Philip Seo, Kerstin Westman, Raashid Luqmani.   

Abstract

The systemic vasculitides are multisystem disorders with considerable mortality and morbidity and frequent relapses. In the absence of reliable serological markers, accurate clinical tools are required to assess disease activity and damage for treatment decisions, and for the performance of clinical trials. This article reviews and summarises the development and use of disease assessment tools for determining activity and damage in systemic vasculitis and reports ongoing initiatives for further development of disease assessment tools. A literature search was conducted using PubMed and reference lists for vasculitis, assessment, clinical trials, outcome and prognosis. The findings indicate that comprehensive disease assessment in vasculitis requires documentation of disease activity, chronic irreversible damage and impairment of function.

Entities:  

Mesh:

Year:  2006        PMID: 16728460      PMCID: PMC1855994          DOI: 10.1136/ard.2005.051078

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  54 in total

1.  Damage occurs early in systemic vasculitis and is an index of outcome.

Authors:  A R Exley; D M Carruthers; R A Luqmani; G D Kitas; C Gordon; B A Janssen; C O Savage; P A Bacon
Journal:  QJM       Date:  1997-06

Review 2.  The socioeconomic impact of vasculitis.

Authors:  M F Cotch
Journal:  Curr Opin Rheumatol       Date:  2000-01       Impact factor: 5.006

3.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

4.  Primary systemic vasculitis: clinical features and mortality.

Authors:  S E Lane; R A Watts; L Shepstone; D G I Scott
Journal:  QJM       Date:  2005-01-17

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

6.  Validity of a vasculitis activity index for systemic necrotizing vasculitis.

Authors:  Q E Whiting-O'Keefe; J H Stone; D B Hellmann
Journal:  Arthritis Rheum       Date:  1999-11

7.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.

Authors:  M Gayraud; L Guillevin; P le Toumelin; P Cohen; F Lhote; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  2001-03

8.  Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis.

Authors:  J K Rao; N B Allen; T Pincus
Journal:  Ann Intern Med       Date:  1998-09-01       Impact factor: 25.391

Review 9.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Authors:  Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

10.  Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

Authors:  Karina A Keogh; Steven R Ytterberg; Fernando C Fervenza; Kimberly A Carlson; Darrell R Schroeder; Ulrich Specks
Journal:  Am J Respir Crit Care Med       Date:  2005-10-13       Impact factor: 21.405

View more
  31 in total

1.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

2.  [EULAR recommendations for the care of patients with small and medium-sized vessel vasculitides].

Authors:  E Reinhold-Keller; K de Groot
Journal:  Z Rheumatol       Date:  2008-12       Impact factor: 1.372

3.  Estimation of BVAS in patients with microscopic polyangiitis in Japan.

Authors:  Mitsuyo Itabashi; Takashi Takei; Taku Morito; Yasuko Yabuki; Hitoe Suzuki; Minoru Ando; Mayuko Akamatsu; Mayuko Yamazaki; Michihiro Mitobe; Yoshihiko Watanabe; Takahiro Mochizuki; Kosaku Nitta
Journal:  Clin Rheumatol       Date:  2011-09-02       Impact factor: 2.980

4.  Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener's).

Authors:  Marcos Martinez Del Pero; Niels Rasmussen; Afzal Chaudhry; Piyush Jani; David Jayne
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-18       Impact factor: 2.503

Review 5.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

6.  Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Authors:  Maria Weiner; Su Mein Goh; Aladdin J Mohammad; Zdenka Hruskova; Anisha Tanna; Annette Bruchfeld; Daina Selga; Zdenka Chocova; Kerstin Westman; Per Eriksson; Charles D Pusey; Vladimir Tesar; Alan D Salama; Mårten Segelmark
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-22       Impact factor: 8.237

7.  Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.

Authors:  Z Chocova; Z Hruskova; H Mareckova; B Svobodova; D Duskova; V Bednarova; E Jancova; R Rysava; V Tesar
Journal:  Clin Rheumatol       Date:  2014-11-12       Impact factor: 2.980

8.  Effects of cyclophosphamide on the prognosis of Japanese patients with renal vasculitis associated with anti-neutrophil cytoplasmic antibody-positive microscopic polyangiitis.

Authors:  Masashi Iwabuchi; Izaya Nakaya; Yoshinori Tsuchiya; Yugo Shibagaki; Takuhiro Yamaguchi; Shunichi Fukuhara; Yuji Oe; Tsutomu Sakuma; Toshinobu Sato; Yoshio Taguma; Jun Soma
Journal:  Clin Exp Nephrol       Date:  2015-11-20       Impact factor: 2.801

9.  Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis.

Authors:  Kiyoki Kitagawa; Kengo Furuichi; Akihiro Sagara; Yasuyuki Shinozaki; Shinji Kitajima; Tadashi Toyama; Akinori Hara; Yasunori Iwata; Norihiko Sakai; Miho Shimizu; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2015-11-20       Impact factor: 2.801

10.  Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

Authors:  Peter A Merkel; Karen Herlyn; Alfred D Mahr; Tuhina Neogi; Philip Seo; Michael Walsh; Maarten Boers; Raashid Luqmani
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.